公开(公告)号：US08673922B2

公开(公告)日：2014-03-18

申请号：US13814384

申请日：2011-07-14

Applicant: Upender Velaparthi ,  David B. Frennesson ,  Mark G. Saulnier ,  Joel F. Austin ,  Audris Huang ,  James Aaron Balog ,  Dolatrai M. Vyas

Inventor： Upender Velaparthi ,  David B. Frennesson ,  Mark G. Saulnier ,  Joel F. Austin ,  Audris Huang ,  James Aaron Balog ,  Dolatrai M. Vyas

IPC: A01N43/54 ,  C07D239/42 ,  C07D401/04

CPC classification number: C07D471/04

Abstract: Disclosed are azaindazole compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein W is CR4 or N; and R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.

Abstract translation: 公开了式（I）的氮杂咔唑化合物或其药学上可接受的盐，其中W是CR 4或N; 并且R 1，R 2，R 3和R 4在本文中定义。 还公开了使用这些化合物治疗至少一种CYP17相关病症例如癌症的方法，以及包含这些化合物的药物组合物。

公开(公告)号：US20100331324A1

公开(公告)日：2010-12-30

申请号：US12666423

申请日：2008-06-26

Applicant: Derek J. Norris ,  Ashvinikumar V. Gavai ,  James Aaron Balog ,  Joel F. Austin ,  Weifang Shan ,  Yufen Zhao ,  Andrew James Nation ,  Wen-Ching Han

Inventor： Derek J. Norris ,  Ashvinikumar V. Gavai ,  James Aaron Balog ,  Joel F. Austin ,  Weifang Shan ,  Yufen Zhao ,  Andrew James Nation ,  Wen-Ching Han

IPC: A61K31/5377 ,  C07D491/18 ,  A61K31/4035 ,  C07D401/14 ,  A61K31/4709 ,  C07D403/14 ,  A61K31/506 ,  C07D413/14 ,  A61K31/4178 ,  C07D401/04 ,  A61K31/4439 ,  A61P35/00 ,  A61P17/10

CPC classification number: C07D491/22

Abstract: Disclosed are fused heterocyclic compounds of Formula (I) or pharmaceutically-acceptable salts or stereoisomers thereof. Also disclosed are methods of using such compounds in the treatment of at least one androgen receptor-associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.

Abstract translation: 公开了式（I）的稠合杂环化合物或其药学上可接受的盐或立体异构体。 还公开了使用这些化合物治疗至少一种雄激素受体相关病症（例如癌症）的方法和包含这些化合物的药物组合物。

公开(公告)号：US20130231354A1

公开(公告)日：2013-09-05

申请号：US13884676

申请日：2011-11-09

Applicant: Joel F. Austin ,  David B. Frennesson ,  Mark G. Saulnier

Inventor： Joel F. Austin ,  David B. Frennesson ,  Mark G. Saulnier

IPC: C07D471/04 ,  C07D487/04

CPC classification number: C07D471/04 ,  C07D487/04

Abstract: Disclosed are azaindazole compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein: Q is: (i) 5-membered heteroaryl comprising at least one nitrogen heteroatom and substituted with zero to 2 Rg; or (ii) 9- to 10-membered bicyclic heteroaryl selected from Formula (II) and; wherein Ring A is a 5- to 6-membered aryl or heteroaryl fused ring substituted with zero to 2 Rg; and R1, R2, R3, and Rg are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.

Abstract translation: 公开了式（I）的氮杂咔唑化合物或其药学上可接受的盐，其中：Q是：（i）包含至少一个氮杂原子并被0至2个R g取代的5元杂芳基; 或（ii）选自式（II）的9至10元双环杂芳基; 其中环A是被0至2个R g取代的5至6元芳基或杂芳基稠环; 并且R1，R2，R3和Rg在本文中定义。 还公开了使用这些化合物治疗至少一种CYP17相关病症例如癌症的方法，以及包含这些化合物的药物组合物。

公开(公告)号：US20130184254A1

公开(公告)日：2013-07-18

申请号：US13814384

申请日：2011-07-14

Applicant: Upender Velaparthi ,  David B. Frennesson ,  Mark G. Saulnier ,  Joel F. Austin ,  Audris Huang ,  James Aaron Balog ,  Dolatrai M. Vyas

Inventor： Upender Velaparthi ,  David B. Frennesson ,  Mark G. Saulnier ,  Joel F. Austin ,  Audris Huang ,  James Aaron Balog ,  Dolatrai M. Vyas

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Disclosed are azaindazole compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein W is CR4 or N; and R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.

Abstract translation: 公开了式（I）的氮杂咔唑化合物或其药学上可接受的盐，其中W是CR 4或N; 并且R 1，R 2，R 3和R 4在本文中定义。 还公开了使用这些化合物治疗至少一种CYP17相关病症例如癌症的方法，以及包含这些化合物的药物组合物。

公开(公告)号：US08067582B2

公开(公告)日：2011-11-29

申请号：US12666423

申请日：2008-06-26

Applicant: Derek J. Norris ,  Ashvinikumar V. Gavai ,  James Aaron Balog ,  Joel F. Austin ,  Weifang Shan ,  Yufen Zhao ,  Andrew James Nation ,  Wen-Ching Han

Inventor： Derek J. Norris ,  Ashvinikumar V. Gavai ,  James Aaron Balog ,  Joel F. Austin ,  Weifang Shan ,  Yufen Zhao ,  Andrew James Nation ,  Wen-Ching Han

IPC: C07D517/00 ,  C07D491/00 ,  A61K31/40

CPC classification number: C07D491/22

Abstract: Disclosed are fused heterocyclic compounds of Formula (I) or pharmaceutically-acceptable salts or stereoisomers thereof. Also disclosed are methods of using such compounds in the treatment of at least one androgen receptor-associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.

Abstract translation: 公开了式（I）的稠合杂环化合物或其药学上可接受的盐或立体异构体。 还公开了使用这些化合物治疗至少一种雄激素受体相关病症（例如癌症）的方法和包含这些化合物的药物组合物。

公开(公告)号：US09266880B2

公开(公告)日：2016-02-23

申请号：US13884676

申请日：2011-11-09

Applicant: Joel F. Austin ,  David B. Frennesson ,  Mark G. Saulnier

Inventor： Joel F. Austin ,  David B. Frennesson ,  Mark G. Saulnier

IPC: C07D487/04 ,  C07D471/04

CPC classification number: C07D471/04 ,  C07D487/04

Abstract: Disclosed are azaindazole compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein: Q is: (i) 5-membered heteroaryl comprising at least one nitrogen heteroatom and substituted with zero to 2 Rg; or (ii) 9- to 10-membered bicyclic heteroaryl selected from Formula (II) and; wherein Ring A is a 5- to 6-membered aryl or heteroaryl fused ring substituted with zero to 2 Rg; and R1, R2, R3, and Rg are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.

Abstract translation: 公开了式（I）的氮杂咔唑化合物或其药学上可接受的盐，其中：Q为：（i）包含至少一个氮杂原子并被0至2个R g取代的5元杂芳基; 或（ii）选自式（II）的9至10元双环杂芳基; 其中环A是被0至2个R g取代的5至6元芳基或杂芳基稠环; 并且R1，R2，R3和Rg在本文中定义。 还公开了使用这些化合物治疗至少一种CYP17相关病症例如癌症的方法，以及包含这些化合物的药物组合物。